Clinical trial
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing…
NCT00043576 · Novacea, Industry · Unknown status
Key facts
| NCT number | NCT00043576 |
|---|---|
| Title | ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere |
| Official title | A Phase 2/3 Multicenter, Randomized, Double Blind Study of Docetaxel (Taxotere) Plus DN-101 or Placebo in Androgen Independent Prostate Cancer (AIPC) |
| Lead sponsor | Novacea, Industry |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | calcitriol, docetaxel |
| Enrollment | 250 |
| Start date | Aug 1, 2002 |
| Completion | Dec 1, 2005 |
| First posted | Aug 13, 2002 |
| Last update posted | Mar 12, 2009 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: